Title : Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.

Pub. Date : 2020 Mar

PMID : 31982639






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVES: We aimed to investigate the clinical efficacy of EGFR tyrosine kinase inhibitor (TKI, T) plus bevacizumab (an antiangiogenic therapy, A) in a real-world population and to provide insights into their mechanism of resistance. Tyrosine epidermal growth factor receptor Homo sapiens